Phase II Trials to Begin in Stroke Treatment

Phase II Trials to Begin in Stroke Treatment

The Canadian company Stem Cell Therapeutics announced via press release that it will soon begin Phase II clinical trials of its NTx(TM)-265 therapy. The therapy involves inducing a patient’s own stem cells to proliferate in the brain, and the company hopes it will be effective for a variety of degenerative neurological disorders. The company’s website says that “neurogenesis-promoting agents” are administered to the patient. In other words, this is a drug treatment and not a treatment based on administration of stem cells.